Related Experiment Video

Updated: Dec 13, 2025

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

12.9K

Cognitive Functions under Anti-HER2 Targeted Therapy in Cancer Patients: A Scoping Review

Javier García-Sánchez1, María D Torregrosa1, Omar Cauli2

  • 1Medical Oncology Department, Doctor Peset University Hospital, Valencia, Spain.

Endocrine, Metabolic & Immune Disorders Drug Targets
|July 31, 2020
PubMed

Insights

Anti-HER2 therapies, like trastuzumab, can impact cognitive function in cancer patients. Further research is needed to understand and manage these side effects for better patient care.

Area of Science:

  • Oncology
  • Neuroscience
  • Pharmacology

Background:

  • HER2-targeted therapies have improved survival for HER2-overexpressing cancers.
  • Adverse effects of cancer treatments, particularly on cognitive function, require further investigation.
  • The impact of anti-HER2 therapies on cognition remains under-explored.

Purpose of the Study:

  • To review the effects of anti-HER2 therapies on cognitive function in cancer patients.
  • To identify specific anti-HER2 drugs and treatment regimens associated with cognitive impairment.
  • To highlight the need for personalized treatment strategies considering cognitive side effects.

Main Methods:

  • Systematic literature search of PubMed, Scopus, Cochrane Library, and Web of Science.
  • Analysis of six studies involving breast and serous uterine cancer patients.
  • Inclusion of preclinical data from gastric cancer mouse models.

Main Results:

  • Four studies reported cognitive function worsening with trastuzumab-containing regimens.
  • Trastuzumab emtansine may cause less cognitive impairment than chemotherapy plus trastuzumab in neoadjuvant breast cancer.
  • Trastuzumab induced cognitive impairment in preclinical gastric cancer models.

Conclusions:

  • Anti-HER2 therapies, particularly trastuzumab, can negatively affect cognitive function.
  • Trastuzumab emtansine shows potential for reduced cognitive side effects.
  • Further preclinical and clinical studies are essential for personalized anti-HER2 treatment and improved quality of life.
Keywords:
Trastuzumabanimal modelsblood-brain barrierbrain.breast cancerpertuzumabside effect

More Related Videos

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

7.7K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
568
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K